20 October 2021

The Alliance Promotion Microbiote presents the results of the first study on the microbiota industry in France

The Alliance Promotion Microbiote presents the results of the first study on the microbiota industry in France 🔵⚪🔴

➖ France is in the top 3 of the most advanced countries in the development of therapies based on the microbiota
➖ The microbiota industry is an opportunity to make France a leader in the production of biomedicines
➖ The study recommends a 3-step action plan to meet the challenges of the sector

“In 2021, there are 118 R&D companies dedicated to the microbiota around the world and 458 drug candidates under development. France, for its part, has 12 companies dedicated to the development of therapies with more than 43 drugs under development and 55 clinical or pre-clinical trials in progress.”

🚀 Aware of the richness of this French ecosystem, Cynbiome has brought together in 2019 some of these private & academics actors within an excellence network to pursue innovative R&D programs and provide a unique #preclinical service offer.

Read the Press Release 👉 https://bit.ly/3maoZ52